Regulations and standards such as GDPR, CQC, and Information Governance can help grow the UK’s private GP EHR market by guaranteeing the secure management of patient data. Reasons for this growth include a decrease in the number of NHS general practitioners and primary care doctors, leading to a rise in demand for private GP services. Tech advancements in the health sector and the integration of AI and wearable tech with EHRs should also boost the market.
FDA approves breast cancer drug
The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor positive, HER2-negative, ESR1-mutated advanced or
